March 24 (Reuters) - Spanish drugmaker Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business. Grifols, which makes drugs using blood plasma, plans to
Grifols Approves IPO of US Biopharma Business to Raise Capital and Cut Debt
Grifols' Strategic Move to Strengthen Financial Position
IPO Approval and Business Structure
March 24 (Reuters) - Spanish drugmaker Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols, which makes drugs using blood plasma, plans to float a minority stake in the biopharma business. The parent company will maintain its listing in Spain and retain majority ownership of the U.S. business.
Vision for Self-Sufficiency
"The transaction reinforces Grifols' vision of self-sufficiency by creating the first and only player that will not rely on plasma, manufacturing or supply from outside the United States," Grifols said.
Financial Goals and Market Expansion
Capital Raising and Debt Reduction
The sale of stake through the IPO would raise capital to strengthen its balance sheet, cut debt and support investments in key markets, it added.
Earnings Growth Outlook
Grifols said in February it expects core earnings to grow by more than a quarter in 2026 and will continue to cut debt, after reporting 2025 profit that more than doubled.
Plasma and Diagnostics Business Growth
The group will continue to grow its plasma and diagnostics businesses in other key markets, it added on Tuesday.
(Reporting by Fabiola Arámburo in Mexico City; Editing by Alan Barona and Shailesh Kuber)
